Clinical efficacy and safety of anti PD-1/PD-L1 antibodies as monotherapy in patients with non-small-cell lung cancer.

Objective: To evaluate the efficacy and safety of anti-PD-1 and anti-PD-L1 immunotherapy agents as monotherapy in patients with non-small cell  lung cancer.

Method: This was a four-year retrospective observational study that included all patients with non-small cell lung cancer treated with  nivolumab, pembrolizumab, and atezolizumab in a third level hospital. Demographic, clinical (ECOG status, stage, PD-L1 expression  level), therapeutic (drug, start date, line of treatment and number of  cycles), efficacy (date and status at the end of follow-up) and toxicity  variables were collected.